Send to

Choose Destination
Clin Transl Gastroenterol. 2017 Jan 19;8(1):e215. doi: 10.1038/ctg.2016.71.

Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients.

Author information

Clinical and Surgical Sciences and Translational Medicine, Sant'Andrea Hospital, School of Medicine, University Sapienza, Rome, Italy.
Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Department of Internal Medicine and Medical Specialties, University Sapienza, Rome, Italy.
Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Divisione di Genetica e Biologia Cellulare, IRCCS San Raffaele Scientific Institute, Milan, Italy.



Circulating autoantibodies targeting the H+/K+-ATPase proton pump of gastric parietal cells are considered markers of autoimmune gastritis, whose diagnostic accuracy in atrophic body gastritis, the pathological lesion of autoimmune gastritis, remains unknown. This study aimed to assess autoantibodies against ATP4A and ATP4B subunits of parietal cells H+, K+-ATPase in atrophic body gastritis patients and controls.


One-hundred and four cases with atrophic body gastritis and 205 controls were assessed for serological autoantibodies specific for ATP4A or ATP4B subunits using luminescent immunoprecipitation system (LIPS). Recombinant luciferase-reporter-fused-antigens were expressed by in vitro transcription-translation (ATP4A) or after transfection in Expi293F cells (ATP4B), incubated with test sera, and immune complexes recovered using protein-A-sepharose. LIPS assays were compared with a commercial enzyme immunoassay (EIA) for parietal cell autoantibodies.


ATP4A and ATP4B autoantibody titers were higher in cases compared to controls (P<0.0001). The area under the receiver-operating characteristic curve was 0.98 (95% CI 0.965-0.996) for ATP4A, and 0.99 (95% CI 0.979-1.000) for ATP4B, both higher as compared with that of EIA: 0.86 (95% CI 0.809-0.896), P<0.0001. Sensitivity-specificity were 100-89% for ATP4A and 100-90% for ATP4B assay. Compared with LIPS, EIA for parietal cell autoantibodies showed a lower sensitivity (72%, P<0.0001) at a similar specificity (92%, P=0.558).


Positivity to both, ATP4A and ATP4B autoantibodies is closely associated with atrophic body gastritis. Both assays had the highest sensitivity, at the cost of diagnostic accuracy (89 and 90% specificity), outperforming traditional EIA. Once validated, these LIPS assays should be valuable screening tools for detecting biomarkers of damaged atrophic oxyntic mucosa.

Conflict of interest statement

Guarantor of the article: Bruno Annibale, MD. Specific author contributions: study design: Edith Lahner, Bruno Annibale, and Vito Lampasona; development of LIPS assays: Cristina Brigatti, Ilaria Marzinotto, Emanuele Bosi, Lorenzo Piemonti, Howard W Davidson, Janet M Wenzlau, and Vito Lampasona; LIPS assays: Ilaria Marzinotto and Vito Lampasona; data analysis: Edith Lahner, Giulia Scalese, Marilia Carabotti, and Bruno Annibale; first draft of the manuscript: Edith Lahner; and all authors contributed to its completion. All authors approved the final draft submitted. Financial support: B.A. acknowledge support from University Sapienza 2013–2014. H.W.D. and J.M.W. acknowledge support from NIH grant R01 DK052068 (to H.W.D.). C.B., I.M., L.P., E.B. and V.L. acknowledge their work was carried out within the framework of the “Ivascomar project, Cluster Tecnologico Nazionale Scienze della Vita ALISEI, Italian Ministry of Research”. Potential competing interests: None.

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center